Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.

ABSTRACT:

Introduction

Acute myeloid leukemia (AML) is the most common and deadly type of leukemia affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed by hematopoietic stem cell transplants, but this is only possible in patients who can tolerate these harsh treatments and many are elderly and frail. With the identification of novel tumor-specific cell surface receptors, there is great conviction that targeted antibody therapies will soon become available for these patients.

Areas covered

In this review, we describe the current landscape of known target receptors for monospecific and bispecific antibody-based therapeutics for AML. Here, we characterize each of the receptors and targeted antibody-based therapeutics in development, illustrating the

SUBMITTER: Morse JW 

PROVIDER: S-EPMC10031751 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature